References
- Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Caraluna JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128: 739–745.
- Smith MP. Non-cystic fibrosis bronchiectasis. The Journal of Royal College of Physicians of Edinburgh. 2011;41: 132–139; quiz 139.
- Barker AF. Bronchiectasis. The New England Journal of Medicine. 2002;246: 1383–1393.
- Chalmers JD, Smith MP, McHugh BI, Doherty C, Govan JR, Hill AT. Shrt- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012:186: 657–665.
- Loeinger MR, Wells AU, Hansell DM, Chinyanganya N, Devajan A., Meister M, et al. Mortality in bronchectasis: A long term study assessing the factors influencing survival. European Respiratory Journal. 2009;34: 843–849.
- Roberts ME, Lowndes L, Milne DG, Wong CA. Socioeconomic deprivation, readmission, mortality and acute exacerbation of bronchiectasis. Internal Medicine Journal. 2012;42: e129–e136.
- Pasteru MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline non-CF bronchiectasis. Thorax. 2010;65(Suppl. 1): 11–58.
- Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine. 2005;12: 205–209.
- King P, Holds Worth S, Freezer N, Holmes P. Bronchiectasis. Internal Medicine Journal. 2006;36: 729–737.
- Cumbaia AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory IM, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine. 2005;4: 117–122.
- Crosbie PAJ, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. European Respiratory Journal. 2009;33: 171–181.
- Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. American Journal of Respiratory and Critical Care Medicine. 1998;157(6 pt 1): 1829–1832.
- Serieri DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respiratory Medicine. 2011;105: 946–949.
- Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest. 2010;138: 1202–1212.
- Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, MAltezos E, Zarogoulidis K. Macrolides from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. European Journal of Clinical Pharmacology. 2012l;68: 479–503.
- Boyton JR, Altmann DM. Bronchiectasis: Current concepts in pathogenesis, immunology, and microbiology. Annual Reviews of Pathology: Mechanisms if Disease, 2016;11: 523–554. [
https://www.annualreviews.org/doi/10.1146/annurev-pathol-012615-044344 accessed online on 23.06.2018]. - Ho JC, Tipoe G, et al, In vitro study of regulation on IL-6 production in bronchiectasis. Respiratory Medicine. 2014;98(4): 334–341.
- Torrado E, Cooper AM. Cytokines in the balance of protection and pathology during mycobacterial infections. Advances in Experimental Medicine and Biology. 2013;783: 121–140.
- King TP. The role of the immune response in the pathogenesis of bronchiectasis. BioMed Research International. 2018;2018: 12.
- Andrei L, Milena AM, Roxana MN, Tudor H, Ioan ST, Beatrice MB, et al. Serum interleukin 4 and 6 levels measured using the ELISA method in patients with acquired bronchiectasis compared to healthy subjects. An anti-inflammatory and pro-inflammatory relation. Revista de Chimie. 2019;70: 2411–2414.
- Zhu J, Qiu Y, Valobra M, Qiu S, Majumdar S, Matin D, De Rose V, Jeffery PK. Plasma cells and IL-4 in chronic bronchitis and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2007;175(11): 1125–1133.
- Yanbaeva DG, Dentener MA, Spruit MA, Houwing-Duistermaat, JJ, Kotz D, Passos VL, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: A case-control study. BMC Medical Genetics. 2009;10: 23.
- Nitescu M, Furtunescu FL, Otelea M, Rafila A, Streinu-Cercel A. Prevalence of metabolic syndrome parameters in a Romanian population of young adults. Revista Romana de Medicina de Laborator. 2012;20(3): 21–28.
- Miotto D, Ruggieri MP, Boschetto P, Cavallesco G, Papi A, Bononi I, et al. Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis. European Respiratory Journal. 2003;22(4): 602–608.
- De Moraes MR, Da Costa AC, Correa Kde S, Junqueira-Kipnis AP, Rabahi MF. Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2014;9: 735–743.
- Ianosi ES, Postolache P, Macovei LA, Szathmary M, Szasz S, Nemes RM, et al. Smoking cessation in COPD patients by a selective partial nicotinic agonist. Revista de Chimie. 2018;69(7): 1766–1769.
- Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JA. IL 4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. The Journal of Immunology. 1999;162: 6233–6237.